Strata Skin Sciences Inc Stock Price, News & Analysis

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announces that John Bagdasarian has been appointed as Vice President of Professional Relations. His role focuses on strengthening relationships in dermatology and leading the company's participation in dermatological meetings. STRATA will be present at the Annual American Academy of Dermatology Meeting from March 25-29, 2022, in Boston. The company's product portfolio includes advanced laser technologies for treating various skin conditions affecting over 31 million patients in the U.S.

STRATA Skin Sciences (NASDAQ: SSKN) announced it will release its fourth quarter and full year 2021 financial results on March 21, 2022, followed by a conference call at 4:30 p.m. ET. The call will review financial performance and provide corporate updates. STRATA focuses on developing innovative dermatological products, including excimer lasers and treatment systems for conditions like psoriasis and acne, targeting a significant patient base in the U.S.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company focused on dermatologic treatment, will participate in the Oppenheimer 32nd Annual Healthcare Conference. Management is set to present on March 15 at 2:00 pm ET and will engage in one-on-one meetings throughout the day. A live and archived webcast of the presentation will be accessible on the company's investor website. STRATA offers advanced products like the XTRAC excimer lasers and TheraClear system, addressing conditions such as psoriasis and acne, impacting over 31 million patients in the U.S.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has appointed Dr. Patricia S. Walker to its Board of Directors, effective February 14, 2022. With over 35 years of experience in dermatology and corporate leadership in medical aesthetics and pharmaceuticals, Dr. Walker's expertise in clinical research and strategic initiatives is expected to enhance STRATA’s operations. Previously, she was the Chief Scientific Officer at Brickell Biotech and has served in key roles at Allergan and Kythera Biopharmaceuticals. Dr. Walker aims to contribute significantly to STRATA’s growth in treating dermatologic conditions and improving patient outcomes.

STRATA Skin Sciences (NASDAQ: SSKN) has launched its next-generation excimer laser system, XTRAC Momentum™ 1.0, in the U.S. The device targets UVB light therapy for skin conditions like psoriasis, atopic dermatitis, and vitiligo. The new system boasts higher power and faster repetition rates, enhancing patient experience. The global treatment market for these conditions surpasses $33 billion, with projected growth. STRATA aims to expand its market footprint with innovative, non-systemic solutions, affirming its commitment to dermatology.

STRATA Skin Sciences has signed an agreement with JuvenIL, a leading distributor in Israel, to market its XTRAC excimer lasers targeting around 300,000 psoriasis and 160,000 vitiligo patients in the country. STRATA’s President & CEO, Robert Moccia, expressed confidence in this partnership as a strategic opportunity to expand into the Israeli market. JuvenIL will leverage its extensive network among over 40 hospitals and 4 Health Maintenance Organizations to commercialize the products effectively.

STRATA Skin Sciences (NASDAQ: SSKN) reported preliminary fourth quarter 2021 revenue between $8.8 million and $9.2 million, up from $6.7 million in Q4 2020. Full-year revenue for 2021 is expected between $29.7 million and $30.1 million, compared to $23.1 million in 2020. Cash and equivalents totaled $12.5 million on December 31, 2021, down from $18.1 million the previous year. The company placed 34 XTRAC systems and expanded its international clinics significantly. STRATA also acquired assets from Theravant Corporation, enabling entry into the $5.5 billion U.S. acne care market.

STRATA Skin Sciences (NASDAQ: SSKN) has announced the acquisition of Theravant Corporation's TheraClear System, enhancing its position in the $5.5 billion acne care market. The deal involves an upfront payment of $1 million, comprising $500,000 in cash and $500,000 in common stock, with additional milestone-based payments. This acquisition allows STRATA to leverage its marketing platform to expand its product offerings beyond acne treatments. TheraClear's FDA-cleared system promises effective in-office treatment for various acne types, aiming to enhance patient compliance and satisfaction.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced participation in the H.C. Wainwright Bioconnect Virtual Conference, with a pre-recorded presentation set for January 10, 2022, at 7:00 am ET. The presentation will be accessible via the investor section of their website. STRATA focuses on innovative dermatology treatments, offering products like XTRAC and Pharos excimer lasers, which treat skin conditions affecting over 31 million patients in the U.S. Their strategy includes direct-to-consumer advertising to boost awareness and support partner clinics through in-house services.